Thrivent Financial for Lutherans Buys New Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Thrivent Financial for Lutherans purchased a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 44,102 shares of the biotechnology company’s stock, valued at approximately $254,000. Thrivent Financial for Lutherans owned 0.21% of Enanta Pharmaceuticals as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ENTA. Krensavage Asset Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 19.7% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after buying an additional 246,736 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Enanta Pharmaceuticals during the third quarter valued at about $903,000. JPMorgan Chase & Co. increased its stake in Enanta Pharmaceuticals by 53.7% during the third quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock worth $2,524,000 after acquiring an additional 85,082 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Enanta Pharmaceuticals by 34.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock worth $1,109,000 after purchasing an additional 49,050 shares during the period. Finally, Wellington Management Group LLP acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $360,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly acquired 45,000 shares of the company’s stock in a transaction on Wednesday, February 12th. The shares were bought at an average cost of $5.69 per share, for a total transaction of $256,050.00. Following the acquisition, the chief executive officer now directly owns 846,638 shares of the company’s stock, valued at $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 13.89% of the stock is currently owned by corporate insiders.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock opened at $4.73 on Friday. The firm has a market capitalization of $100.91 million, a PE ratio of -0.96 and a beta of 0.47. Enanta Pharmaceuticals, Inc. has a one year low of $4.52 and a one year high of $17.24. The stock’s 50 day moving average price is $6.39 and its 200 day moving average price is $8.00.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. On average, analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ENTA. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, JMP Securities reissued a “market outperform” rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.